Kurt Ahmet Arif, Aslan İsmail
Department of Pharmaceutical Technology, Faculty of Pharmacy, Suleyman Demirel University, Isparta 32000, Türkiye.
Department of Pharmaceutical Technology, Hamidiye Faculty of Pharmacy, University of Health Sciences, Istanbul 34668, Türkiye.
Gels. 2025 Feb 26;11(3):165. doi: 10.3390/gels11030165.
L. (H.P.) is a species with a well-documented history of use in wound healing practices across the globe. The objective of this study was twofold: firstly, to evaluate the in vivo efficacy of liposomal in situ gel formulations in wound healing, both clinically and histopathologically, and secondly, to determine the physicochemical characterization of liposomal in situ gel formulations. The in vitro studies will be assessed in terms of particle size, zeta potential, release kinetics, rheological behaviors, and antioxidant and antimicrobial properties. The in vivo studies will be evaluated in clinical animal experiments and pathology studies. The in-situ hydrogel formulations were prepared using the physical cross-linking method with Poloxamer 188, Poloxamer 407, Ultrez 21, and Ultrez 30. The liposome formulations phospholipid 90H and lipoid S100 were prepared using the thin film solvent evaporation method. The antioxidant activity of the samples was evaluated through in vitro studies employing the DPPH antioxidant activity, ABTS+ test, and FRAP test. The antimicrobial activity of the samples was evaluated through the determination of MIC and MBC values employing the 96-well plate method. In vivo, 36 male New Zealand rabbits aged 32-36 weeks were utilized, with six rabbits in each group. The groups were composed of six distinct groups, including conventional and in situ gel liposome formulations of HHPM, three different commercial preparations, and a control group ( = 6). The HHPM-LG8 formulation developed in this study was found to be applicable in terms of all its properties. The new liposomal in situ hydrogel formulation demonstrated notable wound healing activity, a result that was supported by the formulation itself.
L. (H.P.) 是一种在全球伤口愈合实践中有充分使用记录的物种。本研究的目的有两个：第一，从临床和组织病理学角度评估脂质体原位凝胶制剂在伤口愈合中的体内疗效；第二，确定脂质体原位凝胶制剂的物理化学特性。体外研究将从粒径、zeta 电位、释放动力学、流变行为以及抗氧化和抗菌性能方面进行评估。体内研究将在临床动物实验和病理学研究中进行评估。原位水凝胶制剂采用物理交联法，使用泊洛沙姆 188、泊洛沙姆 407、Ultrez 21 和 Ultrez 30 制备。脂质体制剂磷脂 90H 和类脂 S100 采用薄膜溶剂蒸发法制备。通过采用 DPPH 抗氧化活性、ABTS+ 测试和 FRAP 测试的体外研究评估样品的抗氧化活性。通过使用 96 孔板法测定 MIC 和 MBC 值来评估样品的抗菌活性。在体内，使用了 36 只 32 - 36 周龄的雄性新西兰兔，每组 6 只。这些组由六个不同的组组成，包括 HHPM 的常规和原位凝胶脂质体制剂、三种不同的商业制剂以及一个对照组（每组 = 6）。本研究中开发的 HHPM - LG8 制剂在其所有特性方面都被发现是适用的。新的脂质体原位水凝胶制剂显示出显著的伤口愈合活性，这一结果得到了制剂本身的支持。
